| dc.contributor.author | Lane, JD | en_US |
| dc.contributor.author | Tinker, A | en_US |
| dc.date.accessioned | 2017-12-01T12:17:37Z | |
| dc.date.available | 2017-10-20 | en_US |
| dc.date.issued | 2017 | en_US |
| dc.date.submitted | 2017-11-27T14:37:51.415Z | |
| dc.identifier.issn | 1664-042X | en_US |
| dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/29044 | |
| dc.description.abstract | Anti-arrhythmic drugs are a mainstay in the management of symptoms related to arrhythmias, and are adjuncts in prevention and treatment of life-threatening ventricular arrhythmias. However, they also have the potential for pro-arrhythmia and thus the prediction of arrhythmia predisposition and drug response are critical issues. Clinical trials are the latter stages in the safety testing and efficacy process prior to market release, and as such serve as a critical safeguard. In this review, we look at some of the lessons to be learned from approaches to arrhythmia prediction in patients, clinical trials of drugs used in the treatment of arrhythmias, and the implications for the design of pre-clinical safety pharmacology testing. | en_US |
| dc.description.sponsorship | This work was supported by the British Heart Foundation
(FS/12/11/29289 and RG/15/15/31742 and facilitated by the
NIHR Biomedical Research Centre at Barts. | en_US |
| dc.format.extent | 890 - ? | en_US |
| dc.language | eng | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Front Physiol | en_US |
| dc.rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | |
| dc.subject | anti-arrhythmia agents | en_US |
| dc.subject | arrhythmias | en_US |
| dc.subject | cardiac | en_US |
| dc.subject | cardiac ion channels | en_US |
| dc.subject | long QT | en_US |
| dc.subject | torsades de pointes | en_US |
| dc.title | Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology? | en_US |
| dc.type | Article | |
| dc.rights.holder | © 2017 Lane and Tinker. | |
| dc.identifier.doi | 10.3389/fphys.2017.00890 | en_US |
| pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/29163223 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published online | en_US |
| pubs.volume | 8 | en_US |
| dcterms.dateAccepted | 2017-10-20 | en_US |
